Intracellular targeting of CEA results in Th1-type antibody responses following intradermal genetic vaccination by a needle-free jet injection device

TheScientificWorldJournal

Volumn 7, Issue , 2007, Pages 987-999

  Johansson, Susanne ^a,b   Ek, Monica ^a   Wahren, Britta ^a,b   Stout, Richard ^c   Liu, Margaret A ^a   Hallermalm, Kristian ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c Bioject Medical Technologies Inc   (United States)

Author keywords

Antibody response; Biojector; Carcinoembryonic antigen; Genetic vaccination

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PLASMID DNA; TETANUS TOXIN; TUMOR ANTIGEN; DNA VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; GENE AMPLIFICATION; GENE CONSTRUCT; GENETIC CODE; GENETIC IMMUNIZATION; HELPER CELL; HUMAN; HUMAN CELL; JET INJECTION; MEMBRANE BINDING; MOUSE; NEEDLE; NONHUMAN; PROTEIN EXPRESSION; TH1 CELL; WILD TYPE; ANIMAL EXPERIMENT; CELLULAR IMMUNITY; EMBRYO; GENE GUN; IMMUNE RESPONSE; PROTEIN TARGETING; ANIMAL; ANTIBODY SPECIFICITY; HELA CELL; IMMUNOLOGY; INNATE IMMUNITY; INSTRUMENTATION; METHODOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

MUS;

ANIMALS; ANTIBODY SPECIFICITY; CARCINOEMBRYONIC ANTIGEN; DRUG DELIVERY SYSTEMS; HELA CELLS; HUMANS; IMMUNITY, NATURAL; INJECTIONS, JET; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; TH1 CELLS; VACCINES, DNA;

EID: 34250763663     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2007.138     Document Type: Article

References (42)

1. Gurunathan, S., Klinman, D.M., and Seder, R.A. (2000) DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18, 927-974.
2. Boyle, J.S., Koniaras, C., and Lew, A.M. (1997) Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int. Immunol. 9, 1897-1906.
3. Drew, D.R., Lightowlers, M., and Strugnell, R.A. (2000) Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the Tania ovis 45W antigen. Vaccine 18, 2522-2532.
4. Haddad, D., Liljeqvist, S., Stahl, S., Andersson, I., Perlmann, P., Berzins, K., and Ahlborg, N. (1997) Comparative study of DNA-based immunization vectors: effect of secretion signals on the antibody responses in mice. FEMS Immunol. Med. Microbiol. 18, 193-202.
5. Haddad, D., Liljeqvist, S., Stahl, S., Perlmann, P., Berzins, K., and Ahlborg, N. (1998) Differential induction of immunoglobulin G subclasses by immunization with DNA vectors containing or lacking a signal sequence. Immunol. Lett. 61, 201-204.
6. Lewis, P.J., Cox, G.J., van Drunen Littel-van den Hurk, S., and Babiuk, L.A. (1997) Polynucleotide vaccines in animals: enhancing and modulating responses. Vaccine 15, 861-864.
7. Lewis, P.J., van Drunen Littel-van den, H., and Babiuk, L.A. (1999) Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J. Virol. 73, 10214-10223.
8. Rice, J., King, C.A., Spellerberg, M.B., Fairweather, N., and Stevenson, F.K. (1999) Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine 17, 3030-3038.
9. Morel, P.A., Falkner, D., Plowey, J., Larregina, A.T., and Falo, L.D. (2004) DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine 22, 447-456.
10. Widhe, M., Ekerfelt, C., Forsberg, P., Bergstrom, S., and Ernerudh, J. (1998) IgG subclasses in Lyme borreliosis: a study of specific IgG subclass distribution in an interferon-gamma-predominated disease. Scand. J. Immunol. 47, 575-581.
11. Mosmann, T.R. and Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173.
12. Stevens, T.L., Bossie, A., Sanders, V.M., Fernandez-Botran, R., Coffman, R.L., Mosmann, T.R., and Vitetta, E.S. (1988) Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334, 255-258.
13. Papadea, C. and Check, I.J. (1989) Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects. Crit. Rev. Clin. Lab. Sci. 27, 27-58.
14. Brave, A., Ljungberg, K., Boberg, A., Rollman, E., Isaguliants, M., Lundgren, B., Blomberg, P., Hinkula, J., and Wahren, B. (2005) Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol. Ther. 12, 1197-1205.
15. Hallermalm, K., Johansson, S., Bråve, A., Ek, M., Engström, G., Boberg, A., Gudmundsdotter, L., Blomberg, P., Mellstedt, H., Stout, R., Liu, M., and Wahren, B. (2007) Pre-clinical evaluation of a CEA DNA prime / protein boost vaccination strategy against colorectal cancer. Scand. J. Immunol., in press.
16. Sandström, E., Wahren, B., Hejdeman, B., Nilsson, C., Bråve, A., Bratt, G., Robb, M., Cox, J., VanCott, T., Marovich, M., Stout, R., Aboud, S., Bakari, M., Pallangyo, K., Moss, B., Earl, P., Michael, N., Birx, D., Mhalu, F., Wahren, B., and Biberfeld, G. (2006) Multigene, multiclade HIV-1 plasmid DNA prime and MVA boost is safe and highly immunogenic in healthy human volunteers. Antivir. Ther. 11, Supplement 2, 45-46.
17. Lund, L.H., Andersson, K., Zuber, B., Karlsson, A., Engstrom, G., Hinkula, J., Wahren, B., and Winberg, G. (2003) Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. Cancer Gene Ther. 10, 365-376.
18. Beauchemin, N., Benchimol, S., Cournoyer, D., Fuks, A., and Stanners, C.P. (1987) Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen. Mol. Cell. Biol. 7, 3221-3230.
19. Mottola-Hartshorn, C., Lorenzoni, P., and Ceccarini, C. (1988) Biosynthesis and glycosylation of the carcinoembryonic antigen. Biochem. J. 255, 943-948.
20. Huang, E.H. and Kaufman, H.L. (2002) CEA-based vaccines. Expert Rev. Vaccines 1, 49-63.
21. Hefta, S.A., Hefta, L.J., Lee, T.D., Paxton, R.J., and Shively, J.E. (1988) Carcinoembryonic antigen is anchored to membranes by covalent attachment to a glycosylphosphatidylinositol moiety: identification of the ethanolamine linkage site. Proc. Natl. Acad. Sci. U. S. A. 85, 4648-4652.
22. Sack, T.L., Gum, J.R., Low, M.G., and Kim, Y.S. (1988) Release of carcinoembryonic antigen from human colon cancer cells by phosphatidylinositol- specific phospholipase C. J. Clin. Invest. 82, 586-593.
23. Kinugasa, T., Kuroki, M., Yamanaka, T., Matsuo, Y., Oikawa, S., Nakazato, H., and Matsuoka, Y. (1994) Nonproteolytic release of carcinoembryonic antigen from normal human colonic epithelial cells cultured in collagen gel. Int. J. Cancer 58, 102-107.
24. Naghibalhossaini, F. and Ebadi, P. (2006) Evidence for CEA release from human colon cancer cells by an endogenous GPI-PLD enzyme. Cancer Lett. 234, 158-167.
25. Zhang, S., Gu, J., Yang, N.S., Kao, C., Gardner, T.A., Eble, J.N., and Cheng, L. (2002) Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. Prostate 51, 286-292.
26. Hedin, A., Zoubir, F., Lundgren, T., and Hammarstrom, S. (1986) Epitope specificity and cross-reactivity pattern of a large series of monoclonal antibodies to carcinoembryonic antigen. Mol. Immunol. 23, 1053-1061.
27. Glickman, M.H. and Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428.
28. Udenfriend, S. and Kodukula, K. (1995) How glycosylphosphatidylinositol- anchored membrane proteins are made. Annu. Rev. Biochem. 64, 563-591.
29. Turton, K., Chaddock, J.A., and Acharya, K.R. (2002) Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 27, 552-558.
30. Rodriguez, F., Zhang, J., and Whitton, J.L. (1997) DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71, 8497-8503.
31. Tobery, T.W. and Siliciano, R.F. (1997) Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 185, 909-920.
32. Wu, Y. and Kipps, T.J. (1997) Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J. Immunol. 159, 6037-6043.
33. Radcliffe, J.N., Roddick, J.S., Friedmann, P.S., Stevenson, F.K., and Thirdborough, S.M. (2006) Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells. J. Immunol. 177, 6626-6633.
34. Rice, J., Buchan, S., and Stevenson, F.K. (2002) Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J. Immunol. 169, 3908-3913.
35. Rice, J., Elliott, T., Buchan, S., and Stevenson, F.K. (2001) DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J. Immunol. 167, 1558-1565.
36. Kidd, P. (2003) Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8, 223-246.
37. Thompson, C.B. (1995) Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81, 979-982.
38. Jiang, W., Swiggard, W.J., Heufler, C., Peng, M., Mirza, A., Steinman, R.M., and Nussenzweig, M.C. (1995) The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375, 151-155.
39. Sallusto, F., Cella, M., Danieli, C., and Lanzavecchia, A. (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182, 389-400.
40. Choi, A.H., Smiley, K., Basu, M., McNeal, M.M., Shao, M., Bean, J.A., Clements, J.D., Stout, R.R., and Ward, R.L. (2007) Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection. Vaccine 25, 3215-3218.
41. Meseda, C.A., Stout, R.R., and Weir, J.P. (2006) Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D. Viral Immunol. 19, 250-259.
42. Raviprakash, K., Ewing, D., Simmons, M., Porter, K.R., Jones, T.R., Hayes, C.G., Stout, R., and Murphy, G.S. (2003) Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315, 345-352.